Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

The Volume of distribution is 0.13 L/kg.
Candesartan does not penetrate red blood cells.
Absolute bioavailability of candesartan from the administered prodrug, candesartan cilexetil, has been estimated to be about 15%.
During absorption from the gastrointestinal tract, candesartan cilexetil undergoes rapid and complete ester hydrolysis to form the active drug, candesartan.
Elimination of candesartan is primarily as unchanged drug in the urine and, by the biliary route, in the feces. Minor hepatic metabolism of candesartan occurs by O-deethylation to form an inactive metabolite.
Elimination: After oral administration: Renal 33%, Fecal (biliary) 67%.

Key value for chemical safety assessment

Additional information